Literature DB >> 24803232

Prevalence of psoriatic arthritis in psoriasis patients according to newer classification criteria.

Hernán Maldonado Ficco1, Gustavo Citera, José Antonio Maldonado Cocco.   

Abstract

The aim of this study is to determine the prevalence of psoriatic arthritis (PsA) according to Classification of Psoriatic Arthritis (CASPAR) criteria, Assessment of Spondyloarthritis International Society (ASAS) peripheral and axial SpA criteria, and New York criteria for AS. The first 100 patients consecutively attending a psoriasis dermatology clinic were assessed. Demographic and clinical data were collected; all patients were questioned and examined for joint manifestations. Rheumatoid factor and radiographies of hands, feet, cervical spine, and pelvis for sacroiliac joints were obtained. X-rays were read independently by two experienced observers in blind fashion. Patients with objective joint manifestations, both axial and peripheral, were evaluated for fulfillment of CASPAR, ASAS peripheral and axial, and New York criteria. Median age 48 years; 93 % of patients had psoriasis vulgaris and 56 % had nail involvement. Seventeen patients had peripheral arthritis as follows: nine mono/oligoarticular and eight polyarthritis. Median arthritis duration was of 8 years. Seventeen percent of patients fulfilled CASPAR and ASAS peripheral criteria, 6 % New York, and 5 % ASAS axial criteria. Patients who met CASPAR criteria showed a significantly higher psoriasis duration compared to those without arthritis (M 16 vs 10 years, p = 0.02), and a higher frequency of nail involvement (88.2 vs 49.4 %, p = 0.003). Five patients (29.4 %) fulfilled ASAS axial criteria; all of them had peripheral involvement as follows: mono/oligoarticular in three patients and polyarticular in two. Patients with peripheral and axial involvement presented a significantly higher frequency of erythrodermic psoriasis compared to the other patients (35.3 vs 1.2 %, p = 0.0006 and 80 vs 16.7 %, p = 0.02). Prevalence of PsA, for CASPAR and ASAS peripheral criteria, was of 17 %. Five percent of patients met ASAS axial criteria, while 6 % met New York criteria. Worth noting, few patients without signs or symptoms of arthritis had radiological changes, both axial and peripheral, precluding a proper classification.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24803232     DOI: 10.1007/s10067-014-2651-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  19 in total

1.  The latex fixation test. I. Application to the serologic diagnosis of rheumatoid arthritis.

Authors:  C M PLOTZ; J M SINGER
Journal:  Am J Med       Date:  1956-12       Impact factor: 4.965

2.  Incidence and prevalence of psoriatic arthritis: a systematic review.

Authors:  Yannis Alamanos; Paraskevi V Voulgari; Alexandros A Drosos
Journal:  J Rheumatol       Date:  2008-05-01       Impact factor: 4.666

Review 3.  Psoriatic arthritis.

Authors:  D D Gladman
Journal:  Rheum Dis Clin North Am       Date:  1998-11       Impact factor: 2.670

Review 4.  Psoriatic arthritis.

Authors:  J M Moll; V Wright
Journal:  Semin Arthritis Rheum       Date:  1973       Impact factor: 5.532

5.  Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.

Authors:  S van der Linden; H A Valkenburg; A Cats
Journal:  Arthritis Rheum       Date:  1984-04

6.  Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society.

Authors:  S Hukuda; M Minami; T Saito; H Mitsui; N Matsui; Y Komatsubara; H Makino; T Shibata; M Shingu; T Sakou; K Shichikawa
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

7.  In the era of nephelometry, latex agglutination is still good enough to detect rheumatoid factor.

Authors:  Venugopalan Anuradha; Arvind Chopra
Journal:  J Rheumatol       Date:  2005-12       Impact factor: 4.666

8.  The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.

Authors:  M Rudwaleit; D van der Heijde; R Landewé; N Akkoc; J Brandt; C T Chou; M Dougados; F Huang; J Gu; Y Kirazli; F Van den Bosch; I Olivieri; E Roussou; S Scarpato; I J Sørensen; R Valle-Oñate; U Weber; J Wei; J Sieper
Journal:  Ann Rheum Dis       Date:  2010-11-24       Impact factor: 19.103

Review 9.  The early phase of psoriatic arthritis.

Authors:  Dennis McGonagle; Zoe Ash; Laura Dickie; Michael McDermott; Sibel Zehra Aydin
Journal:  Ann Rheum Dis       Date:  2011-03       Impact factor: 19.103

10.  The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal.

Authors:  M Rudwaleit; R Landewé; D van der Heijde; J Listing; J Brandt; J Braun; R Burgos-Vargas; E Collantes-Estevez; J Davis; B Dijkmans; M Dougados; P Emery; I E van der Horst-Bruinsma; R Inman; M A Khan; M Leirisalo-Repo; S van der Linden; W P Maksymowych; H Mielants; I Olivieri; R Sturrock; K de Vlam; J Sieper
Journal:  Ann Rheum Dis       Date:  2009-03-17       Impact factor: 19.103

View more
  5 in total

Review 1.  Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients.

Authors:  Teo Soleymani; Soumya M Reddy; Jeffrey M Cohen; Andrea L Neimann
Journal:  Curr Rheumatol Rep       Date:  2017-11-20       Impact factor: 4.592

2.  Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Authors:  Arthur Kavanaugh; Philip Helliwell; Christopher T Ritchlin
Journal:  Rheumatol Ther       Date:  2016-02-29

Review 3.  Psoriasis and comorbid diseases: Epidemiology.

Authors:  Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2017-03       Impact factor: 11.527

4.  Usefulness of the Psoriatic Arthritis Screening and Evaluation Questionnaire to Monitor Disease Activity in Management of Patients with Psoriasis: Findings from the EPI-PSODE Study.

Authors:  Yong Beom Choe; Chul Jong Park; Dae Young Yu; Youngdoe Kim; Hyun Jeong Ju; Sang Woong Youn; Joo-Heung Lee; Byung Soo Kim; Seong Jun Seo; Seok-Kweon Yun; Joonsoo Park; Nack In Kim; Jai Il Youn; Seok-Jong Lee; Min-Geol Lee; Kwang Joong Kim; Young Suck Ro; Hae Jun Song; Bong Seok Shin; Sung Ku Ahn; Ji Yeoun Lee; Young Ho Won; Min Soo Jang; Ki Ho Kim; Myung Hwa Kim; Tae Yoon Kim; Jee-Ho Choi
Journal:  Ann Dermatol       Date:  2019-01-02       Impact factor: 1.444

5.  Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.

Authors:  Alan J Kivitz; Oliver FitzGerald; Peter Nash; Shirley Pang; Valderilio F Azevedo; Cunshan Wang; Liza Takiya
Journal:  Clin Rheumatol       Date:  2021-09-12       Impact factor: 2.980

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.